Tg Therapeutics (TGTX) Receivables (2010 - 2026)

Tg Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $392.0 million for Q1 2026.

• On a quarterly basis, Receivables rose 2825.72% year-over-year to $392.0 million in Q1 2026; TTM through Mar 2026 was $392.0 million, a 2825.72% increase from a year earlier, with the FY2025 full-year figure at $305.6 million, up 136.58% from the prior year.
• Receivables climbed to $392.0 million in Q1 2026 per TGTX's latest filing, from $305.6 million in the prior quarter.
• Across five years, Receivables topped out at $392.0 million in Q1 2026 and bottomed at $88000.0 in Q2 2022.
• The 5-year median for Receivables is $65.0 million (2024), against an average of $114.6 million.
• Across the five-year window, Receivables slumped 90.55% in 2022 and soared 19768.18% in 2023, its largest moves.
• Year by year, Receivables stood at $88000.0 in 2022, then soared by 57960.23% to $51.1 million in 2023, then jumped by 152.84% to $129.2 million in 2024, then jumped by 136.58% to $305.6 million in 2025, then gained by 28.28% to $392.0 million in 2026.
• Per Business Quant, the three latest TGTX Receivables figures stand at $392.0 million (Q1 2026), $305.6 million (Q4 2025), and $265.4 million (Q3 2025).